BIO Web Conf.
Volume 8, 20172016 International Conference on Medicine Sciences and Bioengineering (ICMSB2016)
|Number of page(s)||6|
|Section||Session I: Medicine|
|Published online||11 January 2017|
Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome
1 College Nursing of Beihua University, 132000, jilin city, jilin province, China
2 Hematology of Affiliated Hospital of Beihua University, 132000, jilin city, jilin province, China
a Corresponding author: Zhenwei Fan: firstname.lastname@example.org
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine combined with half the amount of CAG regimen (decitabine 20mg/m2, once a day, d1-3, Accra neomycin 7mg/m2,intravenous injection, once a day, d4-7, cytarabine 10mg/m2, every 12 hours, d4-10, granulocyte colony stimulating factor 300μg, once a day, d4-10, white blood cell count>20×109/L when deactivated for four courses) and 48 patients in MDS were treated with chemotherapy alone CAG (Accra neomycin 14mg/m2,once a day, d1-3, cytarabine 10mg/m2, every 12 hours, d1-14, granulocyte colony stimulating factor 300μg, once a day, d1-14, white blood cell count>20×109/L when deactivated). Results: Compared with pure CAG, clinical efficacy of decitabine combined with half the amount of CAG regimen is better, the treatment does not increase the risk.
© The Authors, published by EDP Sciences, 2017
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.